CYP2C19 and CYP3A4 activity is associated with survival in ticagrelor-treated patients after ST-elevation myocardial infarction

MÁCHAL, Jan, Ota HLINOMAZ, Katarína KOSTOLANSKÁ, Ondřej PEŠ, Zbyněk ŠPLÍCHAL, Alena MÁCHALOVÁ, Jonáš POKORNÝ, Zuzana MOŤOVSKÁ and Jan JUŘICA. CYP2C19 and CYP3A4 activity is associated with survival in ticagrelor-treated patients after ST-elevation myocardial infarction. In 91st European Atherosclerosis Society Congress. 2023. Available from: https://dx.doi.org/10.1016/j.atherosclerosis.2023.06.627.

Basic information

• Original name: CYP2C19 and CYP3A4 activity is associated with survival in ticagrelor-treated patients after ST-elevation myocardial infarction
• Authors: MÁCHAL, Jan (203 Czech Republic, belonging to the institution), Ota HLINOMAZ (203 Czech Republic, belonging to the institution), Katarína KOSTOLANSKÁ (703 Slovakia, belonging to the institution), Ondřej PEŠ (203 Czech Republic, belonging to the institution), Zbyněk ŠPLÍCHAL (203 Czech Republic, belonging to the institution), Alena MÁCHALOVÁ (203 Czech Republic), Jonáš POKORNÝ (203 Czech Republic), Zuzana MOŤOVSKÁ (703 Slovakia) and Jan JUŘICA (203 Czech Republic).
• Edition: 91st European Atherosclerosis Society Congress, 2023.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30201 Cardiac and Cardiovascular systems
• Country of publisher: Germany
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14110/23:00131611
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1016/j.atherosclerosis.2023.06.627
• Keywords in English: ST-elevation myocardial infarction
• Tags: International impact, Reviewed

Abstract

CYP2C19 and CYP3A4 activity is associated with survival in ticagrelor-treated patients after ST-elevation myocardial infarction - conference abstract.

Links

• GA16-06106S, research and development project: Name: Vysoce efektivní systém založený na kapilární elektroforéze pro screening inhibitorů beta-sekretázy jako terapeutického cíle pro Alzheimerovu chorobu (Acronym: Alzheimer)

Investor: Czech Science Foundation

• MUNI/A/1063/2016, interní kód MU: Name: Experimentální a translační farmakologický výzkum a vývoj

Investor: Masaryk University, Category A